Advice
following a full submission:
nepafenac (Nevanac®) is accepted for use within NHS Scotland.
Indication under review: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
In the pivotal study which included diabetic patients who had undergone cataract surgery, nepafenac eye drops significantly reduced the incidence of macular oedema compared to vehicle.
Download detailed advice131KB (PDF)
Medicine details
- Medicine name:
- nepafenac (Nevanac)
- SMC ID:
- 813/12
- Indication:
- Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.
- Pharmaceutical company
- Alcon Laboratories UK Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 12 November 2012